Kadimastem Announces Executive Management Changes
USA - English
Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO
Company Appoints Biotech Industry Leaders Ronen Twito, CPA as Co-Chairperson and Doron Birger and Ron Mayron to the Company s Board of Directors
News provided by
Share this article
NESS ZIONA, Israel, Feb. 1, 2021 /PRNewswire/
Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announces the appointment of Asaf Shiloni as CEO. This follows a series of executive management appointments in the last month including Mr. Ronen Twito, CPA, as Co-Chairperson of Kadimastem s Board of Directors, and new expert Board members, Mr. Doron Birger and Mr. Ron Mayron. All are highly accomplished biotechnology industry experts, dedicated to working in concert to secure a bright future for the company.
The Romanian mergers and acquisitions (M&A) market recorded 91 transactions in 2020, compared to 110, in 2019. According to Deloitte estimations, the total market value, including the transactions with undisclosed values, was of 3.7-4.3 billion euros in 2020 (compared to 4-4.4 billion euros in 2019), while transactions with disclosed value totalled 1.5 billion euros (compared to 1.7 billion euros in 2019).
“2020 saw a decrease in the number of transactions compared to the previous year, which represented a record for the period after the financial crisis, but, considering the unprecedented general context created by the COVID-19 pandemic, we can say these are good results. A quarterly analysis indicates that the second quarter was the most affected, and the following ones saw a notable revival. 2020 also brought the largest transaction of the last decade: the acquisition of assets owned by CEZ in Romania,” stated